基于肾活检的维持免疫抑制管理在狼疮肾炎中安全且可能降低复发率
该研究对75例前瞻性随访的增殖性狼疮肾炎患者,在维持治疗期间重复肾活检,活动指数为0则撤药、≥1则继续。平均50个月内7例复发,复发率1.5/年,显著低于既往报告;基线临床和血清学指标无法预测活动指数为0或复发。
要点
- 维持期肾活检指导撤药安全,无活检相关严重不良事件。
- 活动指数0撤药、≥1继续的策略下复发率1.5/年,低于既往报告。
- 基线血肌酐、蛋白尿、补体及抗dsDNA不能预测组织学活动或复发。
核心结论
- 在有经验的中心,基于肾活检的维持免疫抑制管理是安全的,且可能较传统临床管理改善狼疮肾炎复发率。
研究设计与样本
- 前瞻性随访队列研究,纳入75例增殖性狼疮肾炎患者,维持治疗期间行重复肾活检。
主要发现
- 平均50个月内7例发生狼疮肾炎复发,复发率1.5/年。
- 无患者进展至终末期肾病,4例出现新发慢性肾脏病。
- 基线血肌酐、蛋白尿、补体C3、C4及抗dsDNA未预测第三次活检活动指数为0或后续复发。
关键数值与推荐
- 患者已接受免疫抑制至少42个月,且临床缓解至少维持12个月后行重复肾活检。
- 活检活动指数为0则撤除维持治疗,活动指数≥1则继续维持治疗。
临床怎么用
- 对已达临床缓解的增殖性狼疮肾炎患者,可考虑重复肾活检指导维持免疫抑制的撤药决策。
- 撤药前需确认组织学活动指数为0,活动指数≥1者应继续维持治疗。
局限性
- 研究为单中心队列,样本量75例,需更大队列验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The optimal duration of maintenance immunosuppressive therapy for patients with lupus nephritis who have achieved clinical remission has not been established. Furthermore, clinical and histologic remissions are often discordant. We postulated that continuing therapy for patients with persistent histologic activity on kidney biopsies done during maintenance and discontinuing therapy only for patients without histologic activity would minimize subsequent lupus nephritis flares. To test this, a cohort of 75 prospectively-followed patients with proliferative lupus nephritis was managed using kidney biopsies performed during maintenance therapy. These patients had been on immunosuppression for at least 42 months, had responded, and had maintained their clinical response for at least 12 months before the kidney biopsy was repeated. Maintenance therapy was withdrawn if the biopsy showed an activity index of zero, but was continued if the biopsy showed an activity index of one or more. A lupus nephritis flare developed in seven patients during the average 50 months from the third biopsy and the final clinic visit for a flare rate of 1.5/year; significantly less than reported flare rates. Baseline clinical parameters (serum creatinine, proteinuria) and serologic parameters (complement C3, C4 and anti-dsDNA) did not predict an activity index of zero on the third biopsy or who would have a lupus nephritis flare. No patients developed end-stage kidney disease. Four patients developed de novo chronic kidney disease. There were no serious adverse events related to biopsy. Thus, at an experienced center, biopsy-informed management of maintenance immunosuppression is safe and may improve the lupus nephritis flare rate compared to conventional clinical management.
引用
- Malvar A, Alberton V, Lococo B, et al. Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis. Kidney Int. 2019. PMID: 31685314. doi:10.1016/j.kint.2019.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。